242 related articles for article (PubMed ID: 21700362)
21. Metallothionein-overexpression as a prognostic marker in melanoma.
Weinlich G
G Ital Dermatol Venereol; 2009 Feb; 144(1):27-38. PubMed ID: 19218909
[TBL] [Abstract][Full Text] [Related]
22. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
[TBL] [Abstract][Full Text] [Related]
23. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
25. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
Crocetti E; Mangone L; Lo Scocco G; Carli P
Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
27. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
[TBL] [Abstract][Full Text] [Related]
28. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
[TBL] [Abstract][Full Text] [Related]
29. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
30. Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting.
Tan KB; Moncrieff M; Thompson JF; McCarthy SW; Shaw HM; Quinn MJ; Li LX; Crotty KA; Stretch JR; Scolyer RA
Am J Surg Pathol; 2007 Dec; 31(12):1902-12. PubMed ID: 18043047
[TBL] [Abstract][Full Text] [Related]
31. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
32. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
33. Lymphovascular invasion as a prognostic factor in melanoma.
Egger ME; Gilbert JE; Burton AL; McMasters KM; Callender GG; Quillo AR; Brown RE; St Hill CR; Hagendoorn L; Martin RC; Stromberg AJ; Scoggins CR
Am Surg; 2011 Aug; 77(8):992-7. PubMed ID: 21944512
[TBL] [Abstract][Full Text] [Related]
34. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
36. Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma.
Ferrari D; Lombardi M; Ricci R; Michiara M; Santini M; De Panfilis G
J Cutan Pathol; 2007 Sep; 34(9):705-12. PubMed ID: 17696918
[TBL] [Abstract][Full Text] [Related]
37. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
38. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma.
Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM
Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123
[TBL] [Abstract][Full Text] [Related]
39. A long-term analysis of 620 patients with malignant melanoma at a major referral center.
Averbook BJ; Russo LJ; Mansour EG
Surgery; 1998 Oct; 124(4):746-55; discussion 755-6. PubMed ID: 9780997
[TBL] [Abstract][Full Text] [Related]
40. Survival analysis of malignant melanoma in Japan--multivariate analysis of prognostic factors.
Uehara S; Kamo R; Harada T; Ishii M
Osaka City Med J; 2009 Jun; 55(1):35-52. PubMed ID: 19725433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
